Engineered multifunctional transforming growth factor-β type II receptor ectodomain fusions for oncology applications
As such, we constructed and characterized specific TβRII-ED-Fc fusions that act as efficient TGF-β ligand traps with picomolar in vitro neutralizing potencies against TGF-β1 and TGF-β3 isoforms, but not TGF-β2. We further demonstrate that TβRII-ED-Fc is a versatile ligand-trapping module that, when combined with a specific targeting moiety, can lead to powerful anticancer biotherapeutics targeted to and retained at the tumor site, by efficiently neutralizing the tumor-promoting activities of TGF-β <i>in vivo</i>.
Authors
- Arsalan S. Haqqani (ORCID: https://orcid.org/0000-0003-2454-8989)
- Laurence Delafosse
- Afnan Abu-Thuraia (ORCID: https://orcid.org/0000-0002-7848-3327)
- Traian Sulea (ORCID: https://orcid.org/0000-0001-5301-8261)
- Marie Parat (ORCID: https://orcid.org/0000-0003-4835-4345)
- Étienne Lessard (ORCID: https://orcid.org/0000-0002-4431-6475)
- Anne E.G. Lenferink (ORCID: https://orcid.org/0000-0001-9825-281X)
- Anna Jezierski (ORCID: https://orcid.org/0000-0002-0837-4678)
- Jason Baardsnes (ORCID: https://orcid.org/0000-0001-5587-3034)
- John C. Zwaagstra (ORCID: https://orcid.org/0000-0002-6551-063X)
- Peter M. Siegel (ORCID: https://orcid.org/0000-0002-5568-6586)
- Sébastien Tabariès (ORCID: https://orcid.org/0000-0003-3513-6111)
- Muhammad Umer Iqbal (ORCID: https://orcid.org/0000-0002-7327-1229)
Institutions
- Medical Council of Canada (CA)
- University of Ottawa (CA)
- McGill University Health Centre (CA)
- Institute for Research in Immunology and Cancer (CA)
- Ste. Anne's Hospital (CA)
- National Research Council Canada (CA)
- McGill University (CA)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-10-27
- DOI
- https://doi.org/10.3389/fonc.2025.1648779
- Primary Topic
- TGF-β signaling in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00